Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

BACKGROUND: Clopidogrel is a prodrug requiring metabolism by cytochrome P450 3A (CYP3A) isoenzymes, including CYP3A5, in order to be active. It is controversial whether clopidogrel interacts with CYP3A inhibitors. We investigated the influence of CYP3A5 polymorphism on the drug interaction of clopid...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Suh, Jung-Won, Koo, Bon-Kwon, Zhang, Shu-Ying, Park, Kyung-Woo, Cho, Joo-Youn, Jang, In-Jin, Lee, Dong-Soon, Sohn, Dae-Won, Lee, Myoung-Mook, Kim, Hyo-Soo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Canadian Medical Association 2006
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1471813/
https://ncbi.nlm.nih.gov/pubmed/16754899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cmaj.060664
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak